Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.
Lead Product(s): Linaprazan
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fourth Swedish National Pension Fund
Deal Size: $25.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 04, 2020